Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 1, 1999, Pages 329-333

  Van Asperen, Judith ^a,c   Van Tellingen, Olaf ^a,c   Schinkel, Alfred H ^a   Beijnen, Jos H ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; VINBLASTINE SULFATE;

ARTICLE; CELL SPECIFICITY; CONTINUOUS INFUSION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG UPTAKE; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE DISTRIBUTION; TISSUE SPECIFICITY; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; HALF-LIFE; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEINS; TISSUE DISTRIBUTION; VINBLASTINE;

EID: 0032919504     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR and Bertino JR (1989) Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
2. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P and Housman DE (1989) The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9:1346-1350.
3. Germann UA (1996) P-glyooprotein: A mediator of multidrug resistance in tumor cells. Eur J Cancer 32:A:927-944.
4. Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DKF, van Asperen J, Borst P and Schinkel AH (1996) Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. Br J Pharmacol 119:1038-1044.
5. O'Brien JP and Cordon-Cardo C (1996) P-glycoprotein expression in normal human tissues, in Multidrug Resistance in Cancer Cells (Gupta S and Tsuruo T eds) pp 285-291, Wiley & Sons, Chichester.
6. Rahmani R and Zhou XJ (1993) Pharmacokinetics and metabolism of Vinca alkaloids. Cancer Surv 17:269-281.
7. Ratain MJ and Vogelzang NJ (1986) Phase I and pharmacological study of vinblastine by prolonged continuous infusion. Cancer Res 46:4827-4830.
8. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM and Borst P (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
9. Schuetz EG, Schinkel AH, Relling MV and Schuetz JD (1996) P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001-4005
10. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol ) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
11. Tang-Wai DF, Kajiji S, DiCapua F, de Graaf D, Roninson IB and Gros P (1995) Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 34:32-39.
12. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I and Willingham MC (1987) Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
13. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Ras 41:1967-1972.
14. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P and van Tellingen O (1996) Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice. J Natl Cancer Inst 88:994-999.
15. van Tellingen O, Beijnen JH, Nooijen WJ and Bull A (1993a) Tissue disposition, metabolism and excretion of vinblastine in mice as determined by high-performance liquid chromatography. Cancer Chemother Pharmacol 32:286-292.
16. van Tellingen O, Beijnen JH, Nooijen WJ and Bult A (1993b) Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography. Cancer Res 53:2061-2065.
17. Zeffren J, Yagoda A, Kelsen D and Winn R (1984) Phase I-II trial of a 5-day continuous infusion of vinblastine sulfate. Anticancer Res 4:411-414.
18. Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, Barra Y and Rahmani R (1993) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions. Cancer Res 53:5121-5126.